Shereen Solaiman - 06 Nov 2026 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
09 Nov 2026, 16:13:37 UTC
Prior SEC filing
16 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
By: Justin Hunter For: Shereen Solaiman
Filing notes and source

Key filing fact

Shereen Solaiman filed Form 4 for MYRIAD GENETICS INC (MYGN) on 09 Nov 2026.

Key facts

  • This page summarizes Shereen Solaiman's Form 4 filing for MYRIAD GENETICS INC (MYGN).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 09 Nov 2026, 16:13.

Change

  • Previous filing in this sequence was filed on 16 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001472827 Primary reporting owner

Solaiman Shereen

Relationship
Chief People Officer
Address
322 NORTH 2200 WEST, SALT LAKE CITY
Signature
By: Justin Hunter For: Shereen Solaiman
Signature date
09 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MYGN transaction Derivative

Time-Based Stock Option

Award

Transaction value
Shares
+83,049
Change %
Price
$0.000000*
Shares after
83,049
Date
06 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
83,049
Exercise price
$5.92
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a one-time non-qualified stock option granted as a retention award under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement.

Footnote F2

The exercise price equals the closing price of the Issuer's common stock on November 6, 2026, the grant date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .